INNOVATIONS IN ONCOLOGY DIAGNOSTICS: TECHNOLOGICAL ADVANCES, GROWTH OPPORTUNITIES AND FUTURE MARKET OUTLOOK
Major developments have been expected in both a IVD marketplace as well as in imaging-based modalities, similar to computed tomography, with a importance being upon a personalized disinfectant approach, where direct will come from physicians, patients as well as payors – all of whom wish some-more in effect treatments as well as worth for money.
This inform analyzes a ultimate innovations in oncology diagnostics as well as identifies a many sparkling brand brand brand brand new technologies as well as trends, trimming from physique imaging as well as cytology to molecular diagnostics as well as pharmacogenomics. The inform additionally identifies a pass hurdles confronting innovative diagnostics companies.
Key Features of this report
•Analysis a ultimate innovations in diagnostics imaging in a oncology sector, covering Magnetic Resonance Imaging (MRI), x-ray, Computed Tomography (CT), ultrasound, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) as well as Flow Cytometry.
•Analyzes a ultimate innovations in molecular diagnostics as well as how they stroke a diagnostics market. The inform covers record together with shimmer in situ hybridization (FISH), polymerase sequence greeting (PCR), HPV testing, immunoassays & biomarkers, microarrays as well as analogous genomic hybridization (CGH).
•Analyzes a ultimate innovations in pharmacogenomics as well as covers a vital applications for patrimonial cancer, breast cancer, colon cancer as well as lung cancer. Also, a inform provides an ubiquitous outlook of a regulatory as well as egghead skill sourroundings for genetic-based tests.
•Looks during a pass blurb hurdles for innovative diagnostics companies, together with a stroke of a recession, reimbursement, regulatory changes, pharmacoeconomics as well as a attribute in in in between attention as well as academia.
The inform Includes in-depth box studies upon a intensity technologies accessible in core areas of un-met need such as ovarian cancer as well as colorectal cancer.
Key benefits of this report
•Understand a ultimate innovations in a oncology diagnostics marketplace in a core areas – evidence imaging, molecular diagnostics as well as pharmacogenetics. This includes marketplace report as well as an investigate of a systematic novel so as to brand what is unequivocally innovative.
•Identify what a pass areas of unmet need have been in a oncology diagnostics marketplace as well as assimilate which products have a biggest intensity over a subsequent decade.
•Understand what a biggest hurdles have been for oncology diagnostics as well as what a many appropriate strategies have been for coping with these obstacles.
•Understand a rival landscape as well as what companies have been heading a approach in conditions of innovation, as well as what a ultimate partnerships per messenger diagnostics.
•Business Insights has identified 5 pass areas of creation in a diagnostics markets, make make use of of this to assistance beam association strategy.
Key commentary from this report
Molecular diagnostics as well as biomarkers have been a pass drivers of a oncology diagnostics market.
Despite a low mercantile recession, R&D spending has hold up for oncology diagnostics companies. However, M&A wake up has been impacted with a worth of deals conducted in 2009 distant next a rise year of 2007.
Partnerships in in in between evidence firms as well as curative firms represents a destiny of a attention as well as a series of messenger deals has been augmenting in a past couple of years.
Virtual colonoscopy – regulating CT scans to set up a design of a colon – is apropos an increasingly supposed pick to invasive colonoscopy for colorectal screening in tall risk groups as well as a ubiquitous population. This presents a sizeable marketplace opportunity.
Interesting investigate is being conducted in both ovarian cancer as well as for prostate cancer, which could have wide-market implications. Specifically, companies have been seeking to countenance brand brand brand brand new biomarkers to emanate some-more correct tests.
Key questions answered by this report
What is a marketplace intensity for in vitro evidence products?
What is a marketplace foresee for oncology diagnostics?
What have been a pass innovations in evidence contrast as well as evidence imaging?
What have been a vital areas of unmet need in oncology diagnostics?
What have been a many earnest record areas in oncology diagnostics, as well as which companies have been exploiting these?
What will be a pass trends impacting a marketplace in a long-term?
How can large pharma entirely feat a opportunities in a oncology diagnostics sector?
Abbott Diagnostics
Affymetrix
Beckman Coulter
Beckton Dickinson
Bio-Rad
Gen-Probe
Johnson & Johnson
Luminex
Nanogen
Roche Diagnostics
Siemens
Sysmex
Table of Contents :
Innovations in oncology diagnostics
Executive outline 10
Setting a stage 10
Innovations in evidence imaging 11
Innovations in molecular diagnostics 12
Innovations in pharmacogenomics 13
Challenges in a oncology diagnostics zone 14
Competitive landscape 15
Chapter 1 Setting a stage 18
Summary 18
Introduction 19
Cancer facts, stream as well as projected 19
History of oncology diagnostics 23
Elements of a cancer diagnosis 26
Pathology 27
Oncology diagnostics marketplace 28
Chapter 2 Innovations in evidence imaging 34
Summary 34
Introduction 35
Body imaging 35
Overview 35
X-ray 38
Breast cancer 38
Computed tomography 40
Lung cancer 40
Colon cancer 40
Others 42
Ultrasound 44
Magnetic inflection imaging 44
Nuclear disinfectant – PET & SPECT 45
Case investigate 47
HYPERImage 47
Cytology 47
Overview 47
Flow cytometry 48
Case investigate 49
CellSearch 49
Cervical screening 50
Cytogenetics 52
Chapter 3 Innovations in molecular diagnostics 56
Summary 56
Introduction 57
DNA, genes as well as chromosomes 59
Fluorescence in situ hybridization (FISH) 59
PCR as well as variants 60
Case investigate 61
HPV contrast 61
Immunoassays as well as biomarkers 62
Case investigate 66
Ovarian cancer 66
PSA contrast 68
Other areas of investigate 70
Epigenomics 71
Microarrays 72
Comparative genomic hybridization (CGH) 73
Case investigate 74
Almac 74
DiaGenic 74
Overview of clinical applications of molecular diagnostics 74
BCR-ABL 74
LOH 75
MSI 75
Chapter 4 Innovations in pharmacogenomics 78
Summary 78
Introduction 79
Familial cancer 79
Breast cancer 80
Colon cancer 81
Melanoma 81
Case investigate 82
IP plea 82
Response to care 83
Cytochrome P450 variants 86
HER2 overexpression 86
The FDA, EMEA as well as PGx labeling 88
Case investigate 89
TheraScreen: KRAS 89
BioTheranostics: Breast cancer 89
Clarient: Breast cancer 90
Marker validation for erlotinib in lung cancer 90
Companion diagnostics 91
Chapter 5 Challenges in a oncology diagnostics zone 94
Summary 94
Introduction 95
Reimbursement appropriation 97
Educated patients = prepared decisions 98
Regulation 99
Pharmacoeconomics 101
Emerging markets 104
Partnerships in in in between drug companies & academia 105
Research & growth 106
Mergers & acquisitions 109
Chapter 6 Competitive landscape 112
Summary 112
Introduction 113
Abbot Diagnostics 113
Affymetrix 114
Beckman Coulter 116
Becton Dickinson 117
Bio-Rad Laboratories 119
Gen-Probe 120
Johnson & Johnson (J&J) 121
Ortho Clinical Diagnostics 121
Luminex 121
Tm Bioscience 122
Nanogen 122
Roche Diagnostics 123
Siemens Healthcare Diagnostics 126
Sysmex 126
Future perspectives in a oncology diagnostics marketplace 127
Science 127
Infrastructure 128
Adoption of creation 130
Companion diagnostics 131
Chapter 7 Appendix 135
Glossary 135
Index 138
List of Figures
Figure 1.1: Leading sites of brand brand brand brand new cancer US, 2009 22
Figure 1.2: Leading sites of brand brand brand brand new cancer in building countries, 2007 23
Figure 1.3: Information compulsory by oncologist pre/post diagnosis 27
Figure 1.4: Oncology diagnostics forecasts ($bn), 2007-14 30
Figure 2.5: Example of a make make use of of of 3D tomosynthesis imaging 39
Figure 2.6: Number of CT scans in a US, 1995-2008 43
Figure 2.7: Women carrying mammograms (%) in a US, 2004* 45
Figure 2.8: Global upsurge cytometry marketplace foresee ($bn), 2008-14 48
Figure 3.9: IV diagnostics marketplace foresee ($bn), 2007-2014) 58
Figure 3.10: Use of biomarkers 63
Figure 3.11: Obstacles to biomarker growth 64
Figure 3.12: US 5-year presence (%) for ovarian cancer during time of diagnosis 67
Figure 4.13: Myriad: Molecular diagnostics sales ($m), 2005-09 83
Figure 4.14: Number of biologics regulated by CDER which have existent PGx report 85
Figure 4.15: Herceptin care price ($) per studious relations to HER2 contrast 87
Figure 5.16: Decline in S&P tellurian zone indices (%), twelve months to Dec 2008 96
Figure 5.17: IV diagnostics risk-based sequence 100
Figure 5.18: FDA certified biomarkers by healing area, Sep 2009 102
Figure 5.19: Roche Diagnostics informal sales (CHFm), 2008 105
Figure 5.20: Leading evidence firms enlarge in R&D outlay (%) y-o-y, 2008 107
List of Tables
Table 1.1: WHO cancer mankind forecasts by segment (‘000), 2008-30 21
Table 1.2: In vitro diagnostics marketplace foresee ($bn), 2008-14 29
Table 2.3: Overview of imaging systems 37
Table 2.4: Mortality rebate (%) attributed to FOBT screening, 1985-96 41
Table 2.5: Organ deviation interpretation from assorted clinical studies 44
Table 3.6: Extensively investigated
Read Also
Pages: 1 2
Tags: Advances, Diagnostics, Future, Growth, Innovations, Market, Oncology, Opportunities, Outlook, Technological